Learn before you link.

MN Pharmaceuticals was established in 1923 and developed a healthcare and pharmaceutical heritage spanning more than a century. In 2012, Amgen acquired MN Pharmaceuticals in a publicly announced transaction. Amgen subsequently renamed the company Gensenta in 2020.

The name rights relating to MN Pharmaceuticals were later transferred to the current MN ownership structure, and MN Nutra represents the fourth-generation continuation of the healthcare heritage that began more than a century ago.

MN Nutra is the fourth-generation continuation of the MN Pharmaceuticals healthcare heritage, combining more than a century of formulation experience with independently developed Micro Matrix Technology and modern finished-product research.

Important: MN Nutra is not owned by, affiliated with, or endorsed by Amgen or Gensenta. The products, technology, and research are independently developed by the current MN ownership structure.

Mehmet Nevzat Pisak, President of MN Nutra, has spent more than 20 years working on pharmaceutical and nutritional formulations designed to improve delivery efficiency, enhance product performance and reduce formulation-related side effects. His publicly searchable patent portfolio includes multiple invention families covering pharmaceutical combinations, gastroprotective approaches, oral delivery systems, curcuminoid formulations and bioavailability-focused compositions.

Key takeaway for affiliates: When discussing heritage, always use the approved language. Say 'fourth-generation continuation of MN Pharmaceuticals healthcare heritage' — never claim affiliation with Amgen or Gensenta. The heritage is about formulation expertise and scientific tradition, not corporate ownership.

Micro Matrix Technology is MN Nutra's proprietary formulation platform. It was independently developed by the current MN ownership structure and is not derived from any Amgen or Gensenta technology.

The core challenge: Many beneficial compounds (curcumin, CBD, beta-glucan) have poor water solubility and low oral bioavailability. This means the body absorbs only a fraction of what you swallow. Micro Matrix Technology addresses this through a multi-stage micronization and matrix-embedding process.

How it works — the seven principles: (1) Particle size reduction to increase surface area. (2) Amorphous solid dispersion to improve dissolution rate. (3) Matrix embedding for stability and controlled release. (4) Surfactant integration for wetting and solubilisation. (5) Gastric protection where needed. (6) Coordinated multi-ingredient release profiles. (7) Manufacturing scalability using GRAS excipients only.

What Micro Matrix delivers: Higher peak plasma concentration (Cmax), greater total exposure (AUC), faster time to peak (Tmax), lower inter-subject variability, and the ability to achieve therapeutic-range blood levels at lower doses.

Evidence: The CBDNext Supra Capsule human PK study (published in Journal of Cannabis Research, 2025) demonstrated 5.7× higher Cmax and 3.3× greater AUC vs standard CBD isolate — providing finished-product human evidence that the Micro Matrix approach translates from formulation science into measurable clinical outcomes.

Key takeaway for affiliates: Micro Matrix is the technology spine that connects all MN Nutra products. It's what makes MN Nutra a platform company, not just a supplement brand. When explaining to customers, focus on 'better absorption means your body can actually use what you're taking' — but never claim it cures or treats any disease.

Stage 1 — Raw Material Selection: Only GRAS (Generally Recognized As Safe) excipients accepted by major regulatory authorities worldwide. Each ingredient is sourced with certificates of analysis, identity testing, and heavy metal screening.

Stage 2 — Micronization: Active compounds are reduced to controlled particle sizes (target: ≥80% of particles ≤10 µm for beta-glucan; similar specifications for curcumin and CBD). This dramatically increases surface area for dissolution.

Stage 3 — Matrix Formation: Micronized actives are embedded within a proprietary solid matrix using specific surfactant-to-active ratios. This creates a stable micro-network that protects the active during storage and transit through the stomach.

Stage 4 — Amorphous Conversion: Where applicable, crystalline compounds are converted to amorphous form during matrix embedding. Amorphous forms dissolve faster than crystalline equivalents because they lack the energy barrier of crystal lattice disruption.

Stage 5 — Stability Optimisation: Each batch undergoes accelerated stability testing. The matrix must maintain particle size distribution, dissolution profile, and assay values through the product's shelf life (typically 24–36 months).

Stage 6 — Finished Dosage Form: The stabilised matrix is filled into capsules, compressed into tablets, or formulated as powder sachets depending on the product line. Each format is tested for dissolution, disintegration, and content uniformity.

Stage 7 — Quality Release: Final products are tested against specification for identity, assay, dissolution, microbiology, heavy metals, and stability. Only batches meeting all specifications are released for distribution.

Patent protection: MN Nutra's patent portfolio includes 65+ filings across PCT, US, European, and national jurisdictions (2019–2026). These cover the specific formulation compositions, not the general concept of micronization.

Key takeaway for affiliates: You don't need to explain all seven stages to customers. The simple message is: 'MN Nutra uses a patented manufacturing process that makes ingredients more absorbable, so your body gets more benefit from each dose.' Always reference that this is backed by a published human study.

Evidence hierarchy — what counts most: (1) Finished-product human studies (strongest — tests the actual product people buy). (2) Ingredient-level clinical studies (strong — tests a key component under clinical conditions). (3) Preclinical/bioavailability studies (supportive — demonstrates the technology works in controlled models). (4) Mechanistic/in-vitro data (background — explains why something should work).

CBDNext Supra Capsule (Level 1 — Finished Product Human Study): Published in Journal of Cannabis Research (2025). Randomized, three-way crossover, 9 healthy adults, 40 mg CBD, fed conditions. Result: 5.7× higher Cmax, 3.3× greater AUC, faster Tmax (2h vs 6h), dramatically lower variability (CV 27% vs 134%). This is the strongest evidence in the MN Nutra portfolio because it tests the actual finished product.

Micronized Beta-Glucan / ImmuCurc (Level 2 — Peer-Reviewed Published Component Studies): Multiple peer-reviewed publications on the micronized beta-glucan component: Kirmaz et al. (2005) in European Cytokine Network — double-blind placebo-controlled Th1/Th2 rebalancing in allergic rhinitis (IL-12↑ p=0.008); Demir et al. (2007) in International Immunopharmacology — monocyte activation in breast cancer patients (+52%, p=0.015); Koray et al. (2009) in J. Alternative & Complementary Medicine — ulcer severity reduction in RAS (p<0.05); plus clinical dossier studies on RTI in children (81% reduction, n=32) and common cold prophylaxis (98.57% symptom-free, n=70). These are published peer-reviewed studies on the key component, not on the complete ImmuCurc formula.

NovoCurmin & CannabiNext (Level 3 — Preclinical Bioavailability): NovoCurmin demonstrated 89 mg/mL water solubility and 14× Cmax improvement vs standard curcumin. CannabiNext showed 57 mg/mL solubility and 88× Cmax improvement. These are preclinical characterisation studies that validate the Micro Matrix technology platform.

GeLiPthin-1 (Level 3 — Preclinical): Preclinical weight management data showing statistically significant results. Contains three proprietary blends: Multi-Path Satiety Blend (1,200 mg), Microbiome & Gut Blend (336 mg), and Thermo-Metabolic Catalyst Blend (128.46 mg). Individual ingredients have published human evidence, but the complete GeLiPthin-1 formula has not yet been tested in a human clinical trial.

Cortexa & Age-Rev TeloNAD+ (Level 4 — Mechanistic): These products are formulated based on published research on individual ingredients (NMN, resveratrol, PQQ, huperzine A, etc.) but do not yet have product-specific clinical data. The evidence is mechanistic and ingredient-level.

Key takeaway for affiliates: Always be honest about evidence level. CBDNext has the strongest proof (published finished-product human study). ImmuCurc's beta-glucan component has multiple peer-reviewed publications (Kirmaz 2005, Demir 2007, Koray 2009) — these are published studies, not just internal data. Others have preclinical or mechanistic support. Never say 'clinically proven' for a product that only has preclinical data.

The FTC Act requires that advertising claims be truthful, not misleading, and substantiated. As an MN Nutra affiliate, you are legally responsible for the claims you make about our products.

APPROVED language (structure/function claims): 'Helps support healthy immune function' · 'Designed to support cognitive performance' · 'Formulated to help maintain healthy weight management' · 'May help support joint comfort' · 'Contains ingredients that support cellular energy production'. Always pair with the FDA disclaimer.

PROHIBITED language (disease claims — NEVER use): 'Cures cancer' · 'Treats diabetes' · 'Prevents Alzheimer's' · 'Reduces tumour size' · 'Lowers blood pressure' · 'Heals inflammation' · 'Anti-viral' · 'Fights COVID'. Any claim that a supplement diagnoses, treats, cures, or prevents a disease is illegal under DSHEA.

Required FDA disclaimer (must appear with any structure/function claim): '*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.'

Testimonial rules: Never fabricate customer reviews or testimonials. If sharing your own experience, it must be truthful and include: 'Individual results may vary.' Never claim typical results unless supported by adequate substantiation.

Income claims: Never guarantee income from the affiliate program. If discussing earnings, you must disclose that results vary and include average earnings data if available. The FTC requires that income claims reflect typical results, not exceptional ones.

Social media requirements: All paid partnerships and affiliate relationships must be clearly disclosed using #ad, #sponsored, or 'Paid partnership with MN Nutra' — placed where viewers will see it before engaging with the content (not buried in hashtags).

Escalation protocol: If a customer asks whether a product can help with a specific medical condition, respond: 'I'm not qualified to give medical advice. Please consult your healthcare provider. I can share information about the ingredients and the published research if that's helpful.' Never diagnose or prescribe.

Key takeaway: When in doubt, ask yourself: 'Am I claiming this product treats or prevents a disease?' If yes, don't say it. Stick to structure/function language ('helps support'), always include the FDA disclaimer, and always disclose your affiliate relationship.